Discovery of novel nitrobenzothiazole inhibitors for Mycobacterium tuberculosis ATP phosphoribosyl transferase (HisG) through virtual screening.
HisG is an ATP-phosphoribosyl transferase (ATPPRTase) that catalyzes the first step in the biosynthetic pathway for histidine. Among the enzymes in this pathway, only HisG represents a potential drug target for tuberculosis. Only a few inhibitors with limited potency for HisG are currently known. To discover more potent and diverse inhibitors, virtual screening was performed. The crystal structure of M. tuberculosis HisG has been solved and reveals a large, solvent-exposed active site with subsites for ATP and PRPP substrates. Two docking algorithms, GOLD and FLEXX, were used to screen two large libraries, Chembridge and NCI, containing over 500000 compounds combined. An initial subset of top-ranked compounds were selected and assayed, and seven were found to have enzyme inhibition activity at micromolar concentrations. Several of the hits contained a nitrobenzothiazole fragment, which was predicted to dock into the monophosphate-binding loop, and this binding mode was confirmed by crystallographic evidence. A secondary screen was performed to identify compounds with similar structures. Several of these also exhibited micromolar inhibition. Furthermore, two of the compounds showed bacteriocidal activity in a whole-cell assay against Mycobacterium smegmatis.
Cho
Yoonsang
Y
Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut, USA.
Ioerger
Thomas R
TR
Sacchettini
James C
JC
D001276:ATP Phosphoribosyltransferase / Q000037:antagonists & inhibitors*; D000465:Algorithms; D001426:Bacterial Proteins / Q000037:antagonists & inhibitors*; D052160:Benzothiazoles / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D001665:Binding Sites / Q000187:drug effects; D018360:Crystallography, X-Ray; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D008958:Models, Molecular; D015394:Molecular Structure; D020102:Mycobacterium smegmatis / Q000187:drug effects* / Q000254:growth & development; D009169:Mycobacterium tuberculosis / Q000201:enzymology*; D054852:Small Molecule Libraries; D013237:Stereoisomerism; D013329:Structure-Activity Relationship; D013499:Surface Properties
D001426:Bacterial Proteins; D052160:Benzothiazoles; D004791:Enzyme Inhibitors; D054852:Small Molecule Libraries; D001276:ATP Phosphoribosyltransferase
Biochemistry. 2006 Dec 19;45(50):14933-43
17154531
Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26
11259830
Proteins. 1999 Nov 1;37(2):228-41
10584068
Arch Biochem Biophys. 1976 Aug;175(2):677-86
183121
J Biol Chem. 2005 Oct 7;280(40):34096-104
16051603
J Med Chem. 1999 Mar 11;42(5):791-804
10072678
Acta Crystallogr D Biol Crystallogr. 2004 Mar;60(Pt 3):432-8
14993666
J Bacteriol. 2003 Nov;185(22):6702-6
14594845
Arch Biochem Biophys. 1977 Jun;181(2):643-8
332083
J Biol Chem. 2003 Mar 7;278(10):8333-9
12511575
Mol Microbiol. 2002 Feb;43(3):717-31
11929527
Biochem Pharmacol. 2000 Feb 1;59(3):221-31
10609550
J Mol Biol. 1997 Apr 4;267(3):727-48
9126849
Acta Crystallogr D Biol Crystallogr. 1997 May 1;53(Pt 3):240-55
15299926
Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12712-7
11606763
Acta Crystallogr D Biol Crystallogr. 1998 Sep 1;54(Pt 5):905-21
9757107
Methods Enzymol. 1997;276:307-26
27754618
Eur J Biochem. 1976 Jul 15;66(3):443-6
60234
J Comput Aided Mol Des. 1997 Sep;11(5):425-45
9385547
Proteins. 2003 Sep 1;52(4):609-23
12910460
J Mol Graph Model. 2002 Jan;20(4):281-95
11858637
Prog Nucleic Acid Res Mol Biol. 2004;78:261-304
15210333
Microbiol Rev. 1996 Mar;60(1):44-69
8852895
J Mol Biol. 2004 Feb 6;336(1):131-44
14741209
Mol Microbiol. 2005 Feb;55(3):675-86
15660995
MMWR Morb Mortal Wkly Rep. 2006 Mar 24;55(11):301-5
16557213
Eur J Biochem. 1975 Dec 1;60(1):103-7
1204631